论文部分内容阅读
为评估年龄对浅表膀胱癌患者膀胱内灌注免疫治疗疗效的影响,作者分析了一组美国全国多中心卡介苗(BCG)加α干扰素(IFN-α)二期临床试验的数据。患者按年龄每10岁递增分组计算开始治疗后2年无复发生存状况。BCG-N组
To assess the effect of age on the efficacy of intravesical immunotherapy in patients with superficial bladder cancer, the authors analyzed data from a phase II clinical trial of BCG plus interferon-alpha in the United States. Patients according to the age of 10-year-old incremental calculation of 2-year relapse-free survival after treatment began. BCG-N group